May D. Lee

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections

Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.